Combining the disparate databases used to detect potential issues with drugs, vaccines and other products into a single dashboard will enhance their utility and cut costs, the agency said.
More early-stage data show the drug, called salanersen, appeared to have positive effects on neurodegeneration and motor function in patients previously treated with Novartis' Zolgensma.
Ugur Sahin and Özlem Türeci, who directed the COVID vaccine maker’s rise to prominence, will helm an as-yet-unnamed company ...
Months after promising help for “hundreds of thousands of kids,” the FDA approved the decades-old medicine for a disease documented in less than 50 people.
The proposed acquisition would hand Servier a couple experimental drugs in human testing as well as Ojemda, an approved ...
Incubated by Atlas Venture, the biotech startup is advancing a daily pill it sees potentially helping people with dystonia or ...
The Zepbound developer is joining other drugmakers’ rush into China as it plans to boost its oral solid dosage supply chain ...
Prasad contributed to an uncertain regulatory climate for gene therapy makers focused on rare conditions. Shares of many ...
Company shares surged in after-market trading on results for a drug Vertex acquired in a multibillion-dollar deal and sees as ...
The therapy, mezigdomide, is part of group of medicines the pharma sees as successors to its lucrative multiple myeloma drugs ...
The Kanakee project builds on the company’s efforts to increase its U.S. footprint, where it has already spent more than $3 ...
The result “pulls the rug” out from under giredestrant, according to one analyst, sparking another share selloff following disappointing obesity data last week.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results